1.	Phase III Randomized Study of Sorafenib Tosylate in Patients With Resected Primary Renal Cell Carcinoma at High- or Intermediate-Risk of Relapse Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
2.	Clinical Trial to Assess the Importance of Nephrectomy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070144, NCT00930033
3.	Phase III Randomized Study of Everolimus Versus Placebo in Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy or Partial Nephrectomy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0931, S0931, NCT01120249
4.	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
5.	Phase III Randomized Study of Everolimus With Versus Without Bevacizumab in Patients With Advanced Renal Cell Carcinoma That Progressed After First-Line Treatment With Tyrosine Kinase Inhibitors Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90802, CALGB-90802, NCT01198158
6.	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
7.	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113387, NCT01235962
8.	IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IMA901-301, 2010-022459-45, NCT01265901
9.	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: CROSS-J-RCC, UMIN000003040, NCT01481870
10.	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
11.	Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AP311736, NCT01599754
12.	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
13.	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784